Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
September 06, 2023 09:20 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
July 14, 2023 07:55 ET
|
SciSparc Ltd
“We hope the outcome of this trial will enable the Company to procced with commercialization process for SCI-210 in Israel" TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 30, 2023 09:25 ET
|
SciSparc Ltd
The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School TEL AVIV, Israel, June 30, 2023 ...
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 21, 2023 09:00 ET
|
SciSparc Ltd
Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
June 02, 2023 09:00 ET
|
SciSparc Ltd
Tel-Aviv, June 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
Impulse Dynamics Announces First Implant for CCM-D™ Clinical Trial
May 18, 2023 07:30 ET
|
Impulse Dynamics
MARLTON, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced the completion of the...
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
May 12, 2023 09:00 ET
|
Clearmind Medicine Inc.
IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind...
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
May 02, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 02, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
April 27, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck
April 19, 2023 04:00 ET
|
Oxford BioTherapeutics
Trial will investigate OBT076 as monotherapy and in sequence with balstilimabCD205, OBT076’s target antigen, is overexpressed in ~ 80 % of ACC tumor biopsy samplesRecurrent or metastatic ACC patients...